Novartis AG (NVS)

NYSE - NYSE Real Time Price. Currency in USD
79.34-0.30 (-0.38%)
At close: 4:02 PM EDT
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close79.64
Bid79.38 x 3100
Ask79.50 x 5300
Day's Range79.28 - 79.65
52wk Range69.90 - 98.95
1y Target EstN/A
Market Cap188.93B
P/E Ratio (ttm)28.33
Avg Vol (3m)1,456,775
Dividend & Yield2.72 (3.41%)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Bloomberg4 hours ago

    Struggling Vaccines From Novartis Turn Into Sales Boon for Glaxo

    Outbreaks of the meningitis B disease in the U.S., along with the social-media frenzy that followed the death of a British toddler, have helped propel sales of GlaxoSmithKline Plc’s vaccine well past initial ...

  • Associated Press10 hours ago

    Novartis wins US OK for biosimilar version of Amgen's Enbrel

    U.S. regulators on Tuesday approved the first lower-cost version of Enbrel, a blockbuster anti-inflammatory drug from Amgen that is among the top-selling drugs in the world.

  • Reuters12 hours ago

    U.S. FDA approves Novartis biosimilar to Amgen's Enbrel

    The U.S. Food and Drug Administration on Tuesday approved Novartis AG's biosimilar version of Amgen Inc's arthritis drug Enbrel. The FDA approved the drug, Erelzi, known also as etanercept-szzs, for multiple inflammatory conditions including rheumatoid arthritis and plaque psoriasis, a skin condition. The agency approved the drug as a biosimilar, meaning there is no clinically meaningful differences between Erelzi and Enbrel.